SLE RA Immunosuppresive agents Immunogenicity to SARS-CoV2 vaccination SLE RA Immunosuppressive therapy Humoral immune response Cellular immune response SARS-CoV-2 vaccine
Conditions
Interventions
SLE patients who get vaccinated with COVID19 vaccine,RA patients who get vaccinated with COVID19 vaccine
Other,Other
SLE patients,RA patients
Sponsors
Ratchadapiseksompotch Fund, Faculty of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 18-65 years old Diagnosis of SLE according to American College of Rheumatology (ACR) 1997 or The Systemic Lupus International Collaborating Clinics (SLICC) criteria or or EULAR/ACR classification Diagnosis of RA according to 2010 ACR and European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis
Exclusion criteria
Exclusion criteria: Pregnancy History of SARS-CoV-2 infection Receipt of covid-19 vaccine prior to study enrollment Severe extra-renal involvement of SLE Receipt of prednisolone > 20 mg/day Receipt of mycophenolate mofetil(MMF) > 1.5 g/day Receipt of azathioprine > 2 mg/kg/day Treatment with cyclophosphamide within 1 month Treatment with biologic agents within the past 6 months Severe SLE flare including: CNS involvement, Vasculitis, Nephritis, Platelet < 60,000, Hemolytic anemia: Hgb < 7 g/dL or decrease in Hgb > 3 g/dL Not receiving immunosuppressive treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Humoral immune response after COVID-19 vaccination 4 weeks after 2nd vaccination AntiRBD, sVNT | — |
Secondary
| Measure | Time frame |
|---|---|
| Cellular immune response after COVID-19 vaccination 4 weeks after 2nd vaccination ELISpot | — |
Countries
Thailand
Contacts
Public ContactTheerada Assawasaksakul
Chulalongkorn University
Outcome results
None listed